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Apathy is one of the most common and pervasive of the
behavioral and psychological symptoms of dementia
(BPSDs). Apathy has profound consequences for morbid-
ity, mortality, and caregiver burden. Treatment of apathy
has been hindered because of poor understanding of the
mechanisms underlying this heterogeneous syndrome.
Research has demonstrated that apathy is associated with
disruption of the frontal-striatal system in individuals with
neurodegenerative disease. As with other BPSDs, these
neural mechanisms alone do not completely account for
the syndrome; individual, caregiver, and environmental
factors also contribute to apathy. In this article, we mod-
ify a current conceptual model of the factors contributing
to BPSDs to examine determinants of apathy. This integra-
tive model provides a more complete and theoretically
informed understanding of apathy, allowing for greater
insight into potential targets for research, intervention,
and care. We end by proposing an agenda for moving the
science of BPSDs in general, and apathy in particular, for-
ward. J Am Geriatr Soc 66:S4–S12, 2018.
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B ehavioral and psychological symptoms of dementia(BPSDs) include changes in behavior, perceptions,
thought content, and mood disturbances such as apathy
and agitation.1 They are among the most troubling
symptoms accompanying neurodegenerative disease and
contribute to many negative outcomes.2,3 Significant chal-
lenges in the management of BPSDs include heterogeneity
of presentation; complexity of underlying neurocognitive
dysfunction; and variety of precipitating individual, care-
giver, and environmental determinants.
We discuss apathy as a prototype BPSD. We chose
this focus for several reasons. First, apathy is one of the
most prevalent and persistent BPSDs across all neurodege-
nerative diseases.4–6 Second, as with many BPSDs, apathy
is a conceptually heterogenous syndrome with varied pre-
sentations, leading to the need to avoid “one size fits all”
approaches to management. Third, there is a larger body
of literature on potential causative mechanisms than for
other BPSDs, indicating that neuroanatomical dysfunction
in part explains the syndrome,7,8 although as with other
BPSDs, neural mechanisms alone do not account for the
syndrome; determinants of apathy may also include indi-
vidual, caregiver, and environmental factors.1,9 We modify
a current conceptual model1 of the factors precipitating
BPSDs to examine mechanisms associated with apathy.
Using the latest findings related to the neurocognitive dys-
function underlying apathy, we extend the model specifi-
cally for this particular syndrome. This integrative model
provides a more complete and theoretically informed
understanding of apathy, allowing for greater insight into
potential targets for research, intervention, and improve-
ment in care. Development and testing of similar models
for other BPSDs is recommended. We end by proposing
an agenda for moving the science of BPSDs in general,
and apathy in particular, forward.
DEFINITION OF APATHY
The word apathy derives from the Greek word pathos or
passion. While describing a state of indifference or iner-
tia,10 over time, the concept of apathy has undergone
changes in meaning but remains vaguely defined and
broadly applied.11 In 1990, Marin defined apathy as a
state of motivational impairment,12 suggesting that apathy
is a syndrome resulting from psychiatric, neurological, or
medical disorders. Although this definition represented an
advance, lack of motivation is difficult to quantify, and it
is not the only cause of apathetic behavior.
From the *College of Nursing, Pennsylvania State University, University
Park; †Frontotemporal Degeneration Center, Department of Neurology,
Perelman School of Medicine, University of Pennsylvania, Philadelphia,
Pennsylvania; and the ‡Program for Positive Aging, Department of
Psychiatry, University of Michigan, Ann Arbor, Michigan.
Address correspondence to Lauren Massimo, PhD, University of




VC 2018, Copyright the Authors
Journal compilation VC 2018, The American Geriatrics Society 0002-8614/18/$15.00
In 2006, Levy and DuBois proposed defining apathy
as “the quantitative reduction of self-generated voluntary
and purposeful behaviors.”13 Consistent with a model of
apathy associated with a deficit in 1 of the 3 determinants
of goal-directed behavior, Levy and DuBois proposed 3
underlying mechanisms responsible for apathy: diminished
emotional-affective processing (motivation), impaired cog-
nitive processing of plans of action (planning), and diffi-
culty in initiating behavior (initiation). In this definition,
apathy can occur when any one of these processes is dis-
rupted. From this perspective, it is possible to observe and
measure the various forms of apathy.7
An international task force published a consensus on
the diagnostic criteria for apathy in neurodegenerative
conditions10 that may resolve some of the discrepancies in
identifying apathy. In these criteria, apathy is described as
a syndrome with cognitive, affective, and behavioral
dimensions. To meet criteria for apathy, the individual
must display the core feature of diminished motivation
and have a reduction in 2 of the 3 following domains:
goal-directed self-initiated or environment-stimulated
behavior, goal-directed cognitive behavior, and emotional
response. Clinical evaluations of individuals with apathy
are challenging because of the variability in each individu-
al’s goals, interests, and emotional displays. Diagnostic cri-
teria such as those that the international task force10
proposed are necessary to operationalize this heterogene-
ous syndrome for reliable diagnosis and for distinguishing
from other syndromes such as depression, and there is a
need for the classification of apathy based on the underly-
ing neural mechanisms that are foundational to the devel-
opment and testing of more precise targeted treatments for
apathy (Table 1).
PREVALENCE
Apathy is a common behavior in neurodegenerative disor-
ders such as Alzheimer’s disease (AD), frontotemporal
degeneration (FTD), Lewy body disease (LBD), and Par-
kinson’s disease (PD). In AD, the prevalence rate of apa-
thy has been estimated to be between 51% and 80%.14–16
Abnormal social behavior is a hallmark symptom of FTD,
and apathy is the most prevalent behavioral disorder,
occurring in 90.5% of individuals with mild FTD and
100% of those with moderate and severe disease.17 The
frequency of apathy in PD and PD-spectrum disorders
such as LBD may also be substantial, although estimates
of prevalence vary more widely than in AD—from 12% to
70%.18–21
Apathy is also one of the most persistent BPSDs. Data
from a population-based longitudinal study found that
apathy was among the most stable of symptoms, having a
62% probability of continuing to be exhibited after 1
year.4 In this study, apathy also had a strong association
with disability, poor health, and mortality.
Table 1. Recommendations for Future Research to Advance Knowledge About Apathy
General Recommendation Evidence of or Rationale for Recommendation
Prospective clinical trials are needed with apathy as a primary outcome
together with important secondary outcomes, such as function.
With few exceptions, apathy has been investigated as a secondary out-
come in retrospective studies
Novel technology approaches including activity-monitoring devices and
eye trackers are necessary for more objective measurement of apathy.
The individual, caregiver or provider often measures apathy
subjectively.
Use of a uniform operational definition of apathy10 and a standard mea-
sure specific to the definition would enhance precision and facilitate
comparison across studies.
Apathy has been described and measured inconsistently in the
literature.
Recruitment of well-characterized samples that meet criteria for specific
types of neurodegenerative disease.
The pathophysiology of apathy may not be the same across the neuro-
degenerative disease spectrum.
Continued study of the neurobiological basis of different apathy
components using neuroimaging techniques.
Without greater neurobiological specificity, it will be difficult to under-
stand the neuroanatomical associations with specific apathy symp-
toms. Greater specificity of apathy subtypes will also help
investigators to more precisely identify treatment targets and to
determine who is likely to respond to specific treatments.
Longitudinal studies of apathy are needed to allow for sufficient time to
observe potential treatment effects.
Intervention trials need to be long enough to detect clinically relevant
effects in the treatment arm and to observe the likelihood of wor-
sening apathy in the control arm. In addition, given apathy’s associ-
ation with conversion to mild cognitive impairment and Alzheimer’s
disease, intervention studies should examine whether efficacious
treatments delay this conversion.
Investigators should consider stabilization of apathy severity to be an
important outcome of intervention, in addition to delay in emergence
or reduction of apathy.
Apathy worsens as dementia progresses, and it is likely that the type
and severity of dementia influences response to pharmacotherapy.
Studies that combine biological and psychosocial approaches are needed
to treat apathy more successfully.
There is a general lack of high-quality research to support the use of
nonpharmacological approaches.
Strong conceptual frameworks that go beyond condition-specific
indicators of treatment success and include person-centered goals are
needed to guide future studies of apathy.
Few, if any, intervention studies include outcomes that reflect goals
and preferences meaningful to people with apathy or their caregiv-
ers. The lived experience of neurodegenerative disease can provide
important ecological insight into meaningful and achievable out-
comes, such as ability to maintain social and physical activity.
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OUTCOMES
Apathy has profound consequences. Accumulating evi-
dence suggests that it is associated with a variety of unde-
sirable outcomes, such as poor insight, poor cognitive
performance, lower functional autonomy, and even greater
mortality.22–25 Apathy has also been identified as an inde-
pendent risk factor for the development of cognitive
impairment in older adults with normal cognition26,27 and
for conversion to dementia in individuals with mild cogni-
tive impairment (MCI).28,29 These findings suggest that
apathy contributes to global decline in cognition and
everyday function and thus support the need to identify
individuals who are at risk of developing it.
PERSPECTIVES OF FAMILY AND PROFESSIONAL
CAREGIVERS
People with neurodegenerative disease tend to be uncon-
cerned about their apathetic behavior, but it is distressing
for their family caregivers.30 Emotional blunting and lack
of response associated with apathy reduce the relational
exchange between the caregiver and care recipient. Care-
givers often misinterpret apathy as oppositional or voli-
tional behavior.31 Spousal caregivers report a loss of
connection to their spouse with apathy that may be related
to impaired emotional responsiveness seen in the syn-
drome.32 In a study of family caregivers, spousal apathy
had the greatest effect on deterioration of the marital
relationship.33
In contrast, formal caregivers may not see apathy as a
significant problem. A recent study of nursing staff in gen-
eral hospitals reported a high frequency of BPSDs in indi-
viduals with dementia, but they did not endorse apathy or
indifference as a distressing symptom.34 Similar findings
have been reported in long-term care settings.35 Nursing
home staff view withdrawal as common in residents, but
rarely is it deemed distressing to staff. Staff distress was
also not associated with dependency in activities of daily
living, a core feature of apathy. Perhaps in the resource-
stressed nursing home environment, “doing for” a resident
is perceived as more expedient than encouraging self-care.
Staff in Australian nursing homes did not endorse lack of
motivation as a challenging behavior,36 a finding similar
to that reported previously.37 In the latter study, many
staff, like family caregivers, viewed symptoms as deliber-
ate, but unlike family caregivers, formal caregivers did not
report high levels of associated distress.
OVERLAP WITH DEPRESSION
Depression and apathy are distinct syndromes that are
often confused. Symptoms common to apathy and depres-
sion include anhedonia, hypersomnia, and fatigue.31,38 A
study that attempted to differentiate apathy from depres-
sion in individuals with AD using factor analysis of the
Hamilton Depression Scale found that psychomotor retar-
dation, agitation, and poor appetite were construed as
apathy factors. Symptoms such as sad mood, guilt, suicidal
ideation, anxiety, and insomnia loaded as a sadness factor,
suggesting that they were more commonly found in people
with depression.39 Other symptoms such as self-criticism
and negative thoughts about the future are common in
people with depression, but absent in individuals with
apathy, who tend to show a lack of concern.40 This is
consistent with similar findings that suggest that apathy is
a discrete syndrome separate from depression.31 Because
apathy is so common in dementia, efforts to distinguish it
from depression are imperative for guiding treatment
decisions.
MEASUREMENTS
There are several apathy assessment tools for use in cogni-
tively impaired individuals. Traditional instruments to
assess for apathy in neurodegenerative disease include rat-
ing scales that commonly rely on proxy report (for review,
see41). Thus, apathy is most often assessed in the context
of the caregivers’ perspective and may therefore be subject
to caregiver confounds such as burden and strain that may
affect the evaluation.42,43
Because apathy is associated with a reduction in motor
behavior, others have proposed the use of objective meas-
urements such as ambulatory actigraphy and computer-
based measurements of apathy.7,43–45 Continued work in
this area is important for the development of an empirically
based, objective approach that elucidates mechanisms con-
tributing to apathy (Table 1). Lastly, use of instruments that
include subscales to measure domains of apathy would
increase the targeted treatment of apathy.41,46
CONCEPTUAL FRAMEWORK FOR EXAMINING
APATHY
We propose an adaptation of Kales and colleagues’ BPSD
conceptual model1 to better understand apathy (Figure 1).
Factors identified in the original conceptual model are
those that may directly cause (neurodegeneration) or indi-
rectly trigger BPSD. The original conceptual model
describes how interactions between the person with
dementia, caregiver, and environment can trigger BPSD in
the context of underlying neurodegeneration.9,47,48
Because this is a conceptual model, the factors listed
include those with a significant evidence base as well as
those that are hypothesized to be important from practice-
based experience. The model is highly useful because it
details the etiological complexity of BPSDs needed for a
thorough clinical assessment and why it is likely that no
single pharmacological or nonpharmacological approach
can be used as a “magic bullet” for treatment. The model
also serves as a basis for researchers to consider in study-
ing the effect of potential etiological causes and triggers of
BPSDs; these studies can lead to better, more customized
interventions than those that we have currently. Because
BPSDs are heterogeneous in their phenotypes (e.g., depres-
sion, psychosis, agitation), have different evidence bases,
and may have different underlying etiologies (e.g., differ-
ent brain regions involved), we believe that there is further
utility to adapting the model for specific BPSDs such as
apathy.
In the specific case of apathy, integrating advances
made in understanding impairments in goal-directed behav-
ior and their related neural mechanisms presents an
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opportunity to further improve the utility of the model for
research. Thus, we have elaborated on the model to include
underlying neurocognitive dysfunction thought to contrib-
ute to apathy, as well as how apathy subtypes may contrib-
ute to symptom heterogeneity (Figure 1). Ideally, this can
advance the field in three ways. First, it provides researchers
and clinicians with an opportunity to consider apathy as
arising directly from disruptions in neurocircuitry or indi-
rectly when such disruptions in neurocircuitry lower the
threshold for (increase vulnerability to) specific personal,
caregiver, and environmental stressors. Second, it suggests
distinct pathways for intervention. Third, it can point the
way toward additional iterations of the model for other
BPSDs such as depression or psychosis, with specific atten-
tion to the neural and nonneural mechanisms pertinent to
those syndromes.
In terms of neurocircuitry disruption, according to
the model that Levy and DuBmois proposed, apathy is
the result of dysfunction in the frontal cortex or struc-
tures in the basal ganglia.13 Three goal-directed behavior
processes map onto 3 distinct brain regions that work
together in a large-scale neural network associated with
apathy. In particular, 3 functional neuroanatomical
loops underlie goal-directed behavior in the frontal area
(anterior cingulate circuit, dorsolateral prefrontal circuit,
orbitofrontal circuit) and appear to capture information
from internal and external environments needed for
enacting goal-directed behavior and performing possible
actions.13 Because each circuit is functionally separate in
supporting individual goal-directed behavior compo-
nents, it may be possible to distinguish different apa-
thetic profiles or subtypes based on underlying
neurocognitive dysfunction.13,49,50
Although the underpinnings of apathy are neurobio-
logical in nature, personal, caregiver, and environmental
factors may exacerbate or trigger apathy symptoms. A
granular understanding of symptom subtype and determi-
nants are critical to the development of effective care strat-
egies that are person and caregiver centered.49
A recent scoping review focusing on BPSDs followed
the Kales conceptual model of BPSDs and used the catego-
ries of personal, caregiver, and environmental determi-
nants as a guide for searching the literature for high-
quality, low-bias studies addressing causes or determinants
of behavioral symptoms. High quality was defined using
Gough’s Weight of Evidence Framework51 and low bias
Figure 1. Conceptual framework for examining apathy.
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using the Cochrane Collaboration bias tool.52 This review
found 16 high-quality, low-bias studies addressing the
causes or determinants of apathy.9 The operational defini-
tion of apathy varied according to study. The most com-
mon instrument used to measure it was the apathy
subscale of the Neuropsychiatric Inventory.53 Informant
report was used most often to rate apathy, which is not
surprising given that reduced insight often co-occurs with
apathy.54,55
Personal Factors
Although apathy is prevalent across dementia types, there
are also some limited and inconsistent data on rates
according to type. One study found that apathy is more
common in behavioral variant FTD than AD. 56 Another
study found that apathy is more common in early- than
late-onset AD.57 A third study of individuals with AD and
vascular dementia found that apathy is more common in
those with vascular dementia, but the results were not
statistically significant.58 In another study, apathy was
most frequent in Dementia with Lewy Bodies (DLB), but
again, the results were not statistically significant.59
The review found strong evidence that apathy is
related to the severity of cognitive impairment in demen-
tia. Apathy was associated with more severe cognitive
impairment according to the Mini-Mental State Examina-
tion60,61 and the Clinical Dementia Rating Scale.62 A prior
study examining specific cognitive deficits in individuals
with AD found that apathy was associated with greater
severity of frontal lobe–related cognitive deficits.63
Several other individual-level determinants have also
been implicated, including the presence of other BPSDs.61
In AD, baseline apathy and antidepressant use are also
associated with increasing apathy over time.64
Biological factors appear to be most strongly associ-
ated with apathy. A number of studies have shown that
neuroanatomical changes in grey and white matter are
associated with apathy.61,64 Apathy also appears to be
associated with genetic factors, including apolipoprotein E
4 in individuals with AD57,65 and c9ORF72 in individuals
with FTD.66 Other biological factors (e.g., cerebral spinal
fluid biomarkers in AD) do not appear to be associated
with apathy.64 Finally, sex does not appear to be related
to apathy.60
Caregiver Factors
In the prior scoping review9, no high-quality evidence of
any caregiver determinant was found, although in observa-
tional studies, it has long been noted that social interac-
tion (or lack thereof) can affect apathy. Other than during
personal care, nursing home residents spend much of their
time “doing nothing,” and negative affect and apathy
have been observed during these unoccupied times.67–70 In
addition, structured interactions that involve caregivers,
such as recreational activities (see discussion on environ-
mental determinants), can reduce apathy and improve
affect.71
More high-quality research is needed on the effect of
caregiver factors, such as communication patterns, on
apathy. For example, caregivers may misinterpret apathy
as oppositional or volitional behavior,32 which may lead
to negative interactions. In long-term care settings,34,35
staff may not intervene because they do not see apathetic
behavior as problematic, leading to exacerbation of
apathy.
Environmental Factors
The prior scoping review found 3 high-quality studies that
evaluated environmental factors. In the first, individuals
with AD participating in activities individualized to per-
sonality and physical ability72 showed less apathy.
Another study of individuals with AD participating in cog-
nitive stimulation also showed positive effects on apathy.73
A third study examining therapeutic conversation, also
demonstrated decreases in apathy in individuals with
AD.74 Prior work in BPSDs suggests that individualized
activities are better than one-size-fits-all interventions for
engaging nursing home residents with dementia. For peo-
ple with apathy, activities that individuals find personally
interesting supply additional intrinsic motivation.75
Because the environment is more modifiable than neuro-
biological deficits, such studies are extremely important.
To summarize, a recent rigorously conducted scoping
review found that most prior studies of determinants have
focused on person-related causes of apathy, particularly
biological factors. The review found strong evidence of an
association between apathy and neurodegeneration,
although most studies previously conducted and consid-
ered for the review were in the area of person-related fac-
tors, with no high-quality caregiver studies found and only
3 high-quality environmental studies found. Additional
work is needed to explore the caregiver and environmental
factors that our adapted conceptual model suggested
(Figure 1), particularly given their greater modifiability
than most person-level factors, such as neurodegeneration.
INTERVENTIONS FOR APATHY
Pharmacotherapy, neuromodulation, and nonpharmaco-
logical approaches are among the interventions currently
used for treating apathy. The evidence to support these
interventions is modest, and there have been no widely
accepted guidelines developed for the management of apa-
thy. Treatment trial failures may relate to the commonly
used simplified definition of apathy used in many trials
(e.g., a lack of motivation); given that neuroanatomical
evidence supports a multicomponent approach to apathy
and that mechanisms underlying apathy are qualitatively
different, different subtypes may require different interven-
tions.49 Again, this is where our adapted model will be
useful for future trials.
Pharmacotherapy
Apathy is associated with neuropathological and neuro-
chemical alterations to frontosubcortical circuits.76 There
are a number of neurotransmitters, receptors, and second
messengers involved in the disruption of these circuits that
form the basis for pharmacotherapy. The evidence for use of
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pharmacological interventions in apathy has been systemati-
cally reviewed46,76–78 and indicates modest efficacy. Few
studies have been conducted, most are retrospective, and
many do not have apathy as a primary outcome. Overall,
cholinesterase inhibitors have the best evidence for sympto-
matic improvement, and there is some evidence for use of
memantine. One clinical trial found no evidence for modafi-
nil in reducing apathy or improving caregiver burden.79
Although the evidence for most stimulants is limited, studies
of the safety and efficacy of methylphenidate are more
encouraging and support findings that apathy may represent
dopaminergic dysfunction. For example, in a recent study of
community-dwelling male veterans with mild AD, those
receiving methylphenidate showed improvement in apathy
scores over a 12-week period.80 To clarify the clinical effi-
cacy of methylphenidate, additional longitudinal studies
such as the Apathy in Dementia Methylphenidate Trial 281
are underway to assess change in apathy and cognition in
individuals with dementia. Finally, there is evidence that
antidepressants and antiepileptics do not improve apathy
and may actually be harmful.
Placebo-controlled trials with apathy as the primary tar-
get that will provide much needed additional data are under-
way. Because apathy has different components (behavioral,
cognitive, affective), each with different underlying mecha-
nisms, future investigations should examine separately the
pharmacological effects on these aspects (Table 1).
Neuromodulation
Neuromodulation approaches to the treatment of apathy
include repetitive transcranial stimulation and transcranial
direct current stimulation. Both approaches are noninva-
sive and deliver magnetic fields through the skull, resulting
in activation or inhibition of the underlying neuronal cir-
cuits involved with the generation of voluntary actions.
Repetitive transcranial stimulation has been efficacious in
the treatment of depression in cognitively intact individu-
als, but there is no strong evidence to support its efficacy
for apathy or depression in people with dementia59 In a
recent randomized clinical trial, transcranial direct current
stimulation had no effect on apathy in people with moder-
ate AD.82
Nonpharmacological Approaches
Several systematic reviews provide evidence of the efficacy
of customized activities (based on the individual’s past his-
tory, preferences, and retained functional abilities).78,83,84
These methodologically heterogeneous interventions
include music therapy, customized activities, cognitive
stimulation, multisensory behavioral therapy, art therapy,
and therapeutic conversation. Theoretically, customized
activities supply intrinsic motivation, a central feature of
apathy, by capturing interest and providing reward. A
challenge to the use of these interventions is that they can
be complex and time consuming, making them difficult to
reproduce and sustain.
There are limited data on the sustained effects of non-
pharmacological interventions for apathy. Kolanowski and
colleagues85 found positive effects of individualized
activities that extended 1 week after the intervention.
Another trial of an individualized functional training pro-
gram significantly reduced apathy 1 month after then
intervention, but at 4 months, apathy levels had
increased.86 Given that apathy often worsens with demen-
tia progression, it is likely that nonpharmacological treat-
ment of apathy will require re-assessment and continuous
programing.
Staff education (a month-long educational program
using nonpharmacological approaches) was investigated in
one study. Although nursing home residents’ emotional
blunting decreased, their level of interest did not increase.87
The investigators noted that lack of staff access to informa-
tion regarding resident preferences was a major barrier to
implementing nonpharmacological interventions for apa-
thy. Poor communication about resident preferences has
been identified as a barrier to person-centered care.88,89
Similar to pharmacological studies, more research is
needed that rigorously uses apathy diagnostic criteria and
considers apathy subtypes to improve precision and effect
sizes (Table 1). Again, our adapted model is well suited for
this. For example, multisensory stimulation may be helpful
in individuals with initiation difficulty, but worsen apathy in
those with planning difficulties (by increasing distractibility).
Studies are needed that determine optimal dosage and dura-
tion of interventions and test strategies to improve imple-
mentation and dissemination of evidence-based approaches.
Finally, because nonpharmacological interventions have long
been recommended as the first line of treatment for apathy,
an updated review of guidelines90 is needed given our cur-
rent understanding of the determinants.
CONCLUSION
We suggest that apathy is a multicomponent phenomenon,
emerging when there is dysfunction in any component of
goal-directed behavior. This adds to a conceptual model
of BPSD by Kales and colleagues that describes how inter-
actions between a person with dementia, caregivers, and
the environment may trigger BPSDs in the context of
underlying neurodegeneration. Thus, it is likely that the
pathophysiology of apathy is not a single mechanism but
is instead multifaceted. It may be possible to identify selec-
tive impairments in goal-directed behavior that contribute
to different clinical phenotypes or subtypes of apathy.49
Understanding mechanisms underlying apathy such as neu-
ral mechanisms of goal-directed behavior in addition to
factors such as those that Kales and colleagues proposed
provide a necessary step forward in proactive, targeted
treatment of apathy.
IMPLICATIONS FOR OTHER BPSDS
The focus here is on apathy in neurodegenerative disease,
but the recommendations for advancing knowledge of this
behavior has implications for other BPSDs. BPSD is an
umbrella term for a variety and range of specific symp-
toms such as aggression, wandering, and depression. Pri-
mary measurement of BPSDs in the aggregate, that is, the
number of symptoms displayed, has diluted the ability to
detect important associations with other variables and the
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effect of interventions on specific symptoms. There is a
need for theoretically informed measures that provide
greater precision in defining and measuring individual
symptoms and syndromes.
Individual symptoms vary over time and according to
type of dementia. Future studies including well-characterized
samples that meet criteria for specific types of neurodegenera-
tion and incorporation of advanced neuroimaging techniques
and other biomarkers of neurodegenerative disease will help
elucidate brain mechanisms that underlie specific symptoms.91
There are many factors in addition to neurodegenerative
disease that precipitate BPSDs, including environmental con-
text and the dyadic relationship with the caregiver. Strong
conceptual frameworks that include these factors are needed
to guide future research studies. Additional iteration of our
apathy model for depressive or psychotic symptoms, with
specific attention paid to the neural and nonneural mecha-
nisms pertinent to those symptoms, would be most helpful.
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